Andrew M. Stuart is a Professor at the California Institute of Technology's Division of Engineering and Applied Science. His research bridges computational mathematics, machine learning, and physical modeling, focusing on inverse problems, partial differential equations, and multiscale systems. He has pioneered methodologies integrating Gaussian processes, Kalman inversion, and neural operators for scientific computing. His recent publications highlight innovations in competitive protein dimerization networks, nonlinear Bayesian inference, and operator learning. Articles span applications in materials science, geophysics, and biochemical signal processing, emphasizing data-driven discovery of differential equations and scalable algorithms for high-dimensional problems. Stuart's work addresses challenges in structural error modeling, uncertainty quantification, and graph-based learning, with implications for climate modeling and dynamical systems. Despite extensive contributions, the scraped data does not specify students, awards, or contact details.
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Jörg F. Löffler is a Full Professor of Metal Physics and Technology at the Department of Materials, ETH Zürich , where he has been since 2003. He previously served as Chairman of the Department (2010–2013) and holds Adjunct Professor positions at Tohoku University (Japan) and a Visiting Faculty role at Caltech. His research focuses on bulk metallic glasses , metallic biomaterials , and magnetic materials , combining synthesis, characterization, and applications in biomedical and structural contexts. Educations : Studied Physics and Materials Science at Saarland University (Germany), earned his doctorate at ETH Zurich and Paul Scherrer Institute on magnetism and neutron scattering (1997). Research Trends : Recent work explores additive manufacturing (e.g., laser powder bed fusion), biodegradable magnesium alloys for implants, and magneto-structural coupling in metallic glasses. Collaborative efforts integrate in situ analysis with computational modeling. Scientific Awards : International Magnesium Science and Technology Award (2023) MRS Fellow (2021) DGM 'Breakthrough' Prize (2016) Masing Memorial Prize (2005) ETH Zurich Medal (1998) Alexander von Humboldt Fellowship (1998-2001) Löffler advises the Department of Materials Science and Engineering at UC Davis and serves on editorial boards. His group at ETH Zürich investigates advanced metallic materials using synchrotron radiation and neutron scattering facilities.
Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.
Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
John M. Woodley is a distinguished Professor in the Department of Chemical and Biochemical Engineering at the Technical University of Denmark (DTU), where he leads research at the PROSYS - Process and Systems Engineering Centre and contributes to the DTU Microbes Initiative. With over 30 years of experience, he has established himself as a leading expert in biocatalysis and bioprocess engineering, with research spanning both theoretical and experimental work across multiple scales. His primary research interests focus on the interface of bioprocess engineering, process chemistry, and reaction engineering. Dr. Woodley's work encompasses multi-step biocatalysis (including systems biocatalysis and flow chemistry), downstream processing from biocatalytic reactors and fermentations (including ISPR), modeling tools for bioprocess assessment (thermodynamics, kinetics, process simulation, economic evaluation), and bio-oxidations (including oxygen supply methods). His enzymatic investigations particularly target alcohol oxidases, carbohydrate oxidases, cytochrome P450s, Baeyer-Villiger monooxygenases, and transaminases. His research portfolio demonstrates consistent innovation in sustainable chemical production, with particular emphasis on enzymatic synthesis of pharmaceuticals and chemicals from renewable resources. Analysis of his recent publications reveals a strong focus on overcoming industrial implementation challenges, particularly regarding enzyme stability in various reactor environments, optimization of multi-enzyme systems, and scale-up methodologies for biocatalytic processes. Dr. Woodley actively supervises multiple PhD students and leads several significant research projects, including 'P450-based biocatalytic processes for the pharmaceutical industry' (2025-2028), 'Integrated model for up- and downstream bioprocess intensification' (2024-2027), and 'ENFACE: A tool for prediction of enzyme stability at gas-liquid interfaces' (2024-2027). His work has resulted in an impressive publication record of 781 research outputs across various formats, including journal articles, book chapters, and conference proceedings. His research group operates within the Department of Chemical and Biochemical Engineering at DTU, utilizing advanced facilities for biocatalysis research, including specialized reactor systems for studying gas-liquid interfaces, computational modeling resources, and laboratories for enzyme characterization and bioprocess development. Through his leadership in the PROSYS center, he contributes to DTU's strategic focus on sustainable process technologies and systems engineering.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
David Leigh is a Professor in Organic Chemistry at the University of Manchester , UK. He has held prestigious positions including the Sir Samuel Hall Chair (2014–present), Forbes Chair at the University of Edinburgh (2001–2012), and Chair of Synthetic Chemistry at the University of Warwick (1998–2001). His research focuses on synthetic molecular machines, supramolecular chemistry, and molecular knots. Fields of Scholarship : Synthetic molecular machines, Synthetic molecular knots and links, Supramolecular chemistry His work includes creating hydrogen-bonded molecular rotors , reversible rotary molecular motors , and artificial ribosome mimics . Article trends highlight nanotechnology , molecular engineering , and self-assembly advancements. Scientific Awards : Royal Society of Chemistry Pedler Award (2014), ERC Advanced Grant (2014), Bakerian Prize (2013), Tilden Prize (2010), Fellow of the Royal Society (2009), etc. Leigh has led groundbreaking projects funded by the European Research Council (2008, 2014) and held an EPSRC Senior Research Fellowship (2005–2010). His lab at the University of Manchester explores bottom-up molecular design and stimuli-responsive systems.
David R. Koes is an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh, affiliated with the School of Medicine. He holds roles such as Associate Director of the Joint CMU-Pitt Computational Biology PhD Program (CPCB) and is involved in multiple graduate programs including Intelligent Systems and Computational Biomedicine. His research focuses on developing computational algorithms and systems for drug discovery, emphasizing open-source software and machine learning applications in biomedical data. Koes teaches courses like MSCBIO2025 (Bioinformatics Programming in Python) and MSCBIO2065 (Scalable Machine Learning for Big Data Biology). He has secured NIH funding (R35GM140753) and collaborated on projects with institutions like NVIDIA and Google Cloud. His lab develops tools such as GNINA, Pharmit, and 3Dmol.js, and actively contributes to open drug discovery initiatives. Education: PhD in Computer Science from Carnegie Mellon University (CMU). Research Interests: Leveraging computation and AI for drug design, molecular docking, pharmacophore modeling, and open science. Specific areas include developing scalable machine learning pipelines, virtual screening systems, and tools for 3D molecular analysis. Grants and Funding: Current NIH R35 grant and prior support from NSF, Relay Therapeutics, and others. His work emphasizes translating computational methods into practical drug discovery solutions. Lab and Teams: Directs a lab focused on computational drug discovery, collaborating with multiple academic and industry partners. Supervises graduate students and postdocs in projects spanning AI-driven drug design, molecular modeling, and software development.
Professor Knut Reinert is a leading figure in algorithmic bioinformatics at the Free University of Berlin, where he holds a professorship in the Department of Mathematics and Computer Science. He also maintains a significant affiliation with the Max Planck Institute for Molecular Genetics in Berlin, where he leads the Efficient Algorithms for Omics Data group. His research spans both institutions through the Reinert Lab, which focuses on developing novel computational approaches for biological data analysis. Reinert's educational background includes a Diploma in Computer Science (1994) and a Doctorate (Dr. Ing./Ph.D., 1999, with honors) from the Max-Planck-Institut for Computer Science and Universität des Saarlandes in Saarbrücken. Prior to his professorship, he worked as a computer scientist under Prof. Gene Myers at Celera Genomics in Rockville, USA (1999-2002). His primary research interests center on algorithmic bioinformatics with specific focus on developing novel algorithms and data structures for biomedical mass data analysis. This includes creating mathematical models for genomic sequence analysis and algorithms for mass spectrometry data to detect differential protein expression between normal and diseased samples. His work bridges the gap between computational tool development and practical biological applications, with particular emphasis on NGS and proteomics data. The publications and projects led by Prof. Reinert demonstrate a consistent focus on advancing computational methods in bioinformatics. His research spans genomic sequence analysis, RNA research (particularly long non-coding RNAs), parallel computing applications, and GPU acceleration for biological data processing. The work shows increasing sophistication in handling large-scale biological datasets through innovative algorithmic approaches. Intel® Parallel Computing Center designation for his lab CUDA Research Center status DFG funding of 530 thousand Euros for RNA research de.NBI funding of 2 million Euros BMBF funded projects 'LIVE-DREAM' and 'EssBar' Prof. Reinert leads multiple significant research projects and has established strong collaborations with international partners including Texas A&M, Kings College London, Eberhardt-Karls Universität Tübingen, Robert-Koch-Institute, and various Turkish institutions. His lab receives funding from major organizations including DFG, BMBF, and Intel. The Reinert Lab maintains active teaching responsibilities at FU Berlin, offering courses at BSc, MSc, and PhD levels using both traditional and innovative learning concepts like e-learning and inverted classrooms. The Reinert Lab consists of two interconnected research groups that work closely with experimental biologists and medical researchers to develop practical computational solutions for real-world biological problems. The lab has established itself as a key player in the German and international bioinformatics community through its development of the widely-used SeqAn library and participation in national infrastructure initiatives.
